Genzyme, a Sanofi company (SNY: Quote), and Veracyte, Inc.,said Monday that the Afirma Thyroid FNA Analysis, an innovative approach for improved thyroid nodule diagnosis, is now available to patients across the United States.
The Afirma Thyroid FNA Analysis combines expert cytopathology assessment of thyroid nodule fine needle aspiration samples, with the Afirma Gene Expression Classifier, a novel genomic test, used to resolve inconclusive results and thus help patients whose nodules are actually benign avoid unnecessary surgery.
Two independent clinical studies to date have shown that the Afirma Gene Expression Classifier can reclassify patients with indeterminate thyroid FNA results as "benign" with the same degree of accuracy as a benign cytopathology diagnosis.
Click here to receive FREE breaking news email alerts for Sanofi and others in your portfolio
by RTT Staff Writer
For comments and feedback: editorial@rttnews.com
Business News